ODE V Permanent Director Bull Brings Women’s Health, Analgesics Expertise
This article was originally published in The Tan Sheet
Executive Summary
Jonca Bull, MD, will tackle Rx-to-OTC switch issues head-on in her first week as permanent director of FDA's Office of Drug Evaluation V
You may also be interested in...
ODE V deputy director
Brian Harvey, MD/PhD, appointed deputy director, Office of Drug Evaluation V, effective May 30, FDA announces. Harvey joined FDA in 1995 as a medical officer and has served in clinical review and management positions at both CDRH and CBER. He is involved in FDA interagency collaborations with NIH, CDC and has served as FDA liaison to several professional societies and industry groups, agency notes. Harvey graduated from Middlebury College and received a PhD in biochemistry and an MD at the University of Connecticut. He will report to Jonca Bull, MD, who became director of ODE V roughly a year ago (1"The Tan Sheet" June 3, 2002, p. 13). One of Harvey's first tasks involving the Division of OTC Drug Products could be attending the upcoming NDAC meeting on ipecac...
FDA Generics Office To Revise BCS Waiver Guidance Under Science Director
FDA's Office of Generic Drugs is planning to revise the final guidance on biopharmaceutics classification system-based biowaivers under the leadership of Director for Science Lawrence Yu, PhD
Prilosec 1 Switch For Heartburn Prevention, 14-Day Use To Be Considered
OTC omeprazole will return for a second FDA advisory committee review June 21 with a revised indication and recommended duration of use